Opus Genetics Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its pivotal Phase 3 clinical trial, LYNX-3. The study is evaluating Phentolamine Ophthalmic Solution 0.75% for treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. This trial follows the positive topline results of the earlier LYNX-2 Phase 3 trial announced in June 2025. The LYNX-3 study, which is the second Phase 3 trial for this indication, is being conducted with Fast Track designation and under a Special Protocol Assessment from the U.S. Food and Drug Administration. Results from this ongoing trial are yet to be presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523070-en) on September 04, 2025, and is solely responsible for the information contained therein.